1. Der „Shengya-Deal“...- eine Punktlandung für Mr. Zhang (2010)
Hiermit „holte sich“ der Sunwin President und Chairman, Mr. Laiwang Zhang, die komplette Firma Shengya gegen einen Großteil seiner Sunwin-Aktien zurück:
"...Shengya manufactures ...sells a variety of veterinary medicines in China that historically represents less than 20% of the total revenues of the Company and represented approximately 12% of the total revenues of the Company in its fiscal year ended April 30, 2010 compared to 16.7% in the fiscal year ended April 30, 2009....Under the terms of the Agreement, the purchase price for the 100% ownership interest in Shengya is $5,003,869, the net book value of Shengya’s assets (total assets minus total liabilities) as set forth on its consolidated balance sheet as of April 30, 2010 (the “Purchase Price”). Upon closing of the transaction, Mr. Zhang will pay the Purchase Price by cancelling 7,818,545
shares of the Company’s common stock he owns (the “Cancelled Shares”). The value of the Company’s common stock for purposes of computing the number of Cancelled Shares was the average of the closing price of the stock over the 10 trading days prior to the date of the Agreement. The transaction is expected to close on July 31, 2010.....“
Wohlgemerkt: „10 trading days prior to the date of the Agreement“, dabei würde ich davon ausgehen, dass es sich um die 10 Tage vor dem 29. Juni handelt, denn etwas weiter oben in diesem Filing heißt es:
" On June 29, 2010 Qufu Natural Green Engineering Co., Ltd. (“Qufu Natural Green”) a wholly owned subsidiary of Sunwin International Neutraceuticals, Inc. (the “Company”) entered into a Stock Sale and Purchase Agreement (the “Agreement”) to sell its 100% ownership interest in Shengya Veterinary Medicine Co., Ltd. (“Shengya”) to Mr. Laiwang Zhang, the Company’s President and Chairman of its Board of Directors".
www.sec.gov/Archives/edgar/containers/...810000140/suwn8-k.htm